BPS 2018


Chirality, Alzheimer’s Disease, and Amyloid Beta

Jevgenij Raskatov

Assistant Professor in Biochemistry and Chemistry, University California Santa Cruz

ABSTRACT

Chirality is of para­mount im­por­tance to all living systems. It is a property of all principal bio­mo­le­cular buil­ding blocks, i.e., amino acids except glycine, sugars and nucleosides, as well as lipids. Continuous improvement of preparative metho­dologies meanwhile allows increasingly complex mole­cules to be synthesized, which includes so­phi­s­ti­ca­ted mirror-image biomolecules, such as proteins.
Aggregation-prone (amyloidogenic) polypeptides are produced by living systems, often as cleavage products of substantially larger protein precursors. Whereas their functions in health are challenging to study and not always well understood, it is widely accepted that an imbalance between their production and clearance can trigger a range of pathological conditions, including Alzheimer’s Disease (AD / amyloid β, Aβ), Huntington’s Disease (HD / the huntingtin protein) and Type 2 Diabetes (T2D / amylin). A feature that is common to all those peptides is the high polydispersity across both aggregate size and shape, with distinctions frequently made between oligomers, protofibrils and fibrils. In sporadic AD, Aβ oligomers (especially those derived from the 42-amino acid long isoform, Aβ42) are believed to be particularly harmful, whereas fibrils appear to represent an aggregation endpoint that may be relatively benign.

Peptide backbone conformations can be altered through introduction of D-amino acids (“Chiral Editing”), and replacement of L- by D-amino acids across the entire peptide yields mirror image (“D-“)Aβ. Because of the enantiomeric relation, D-Aβ has to possess an identical oligomer-pro­to­fibril-fibril distribution to that of the natural (“L-“) stereoisomer. However, all 3D-structural para­meters are mirrored in D-Aβ42, including the peptide backbone. Through stereochemical argu­ments, we envisioned that racemic Aβ42 should exhibit increased fibril formation and reduced toxicity. We synthesized the two enantiomers of Aβ42 and found that their equimolar mixture exhibited pronounced acceleration of fibril formation, as compared to the enantiopure coun­ter­parts. This led to substantial suppression of oligomer formation and inhibition of toxicity in model cell-based systems. We termed this the “Chiral Inactivation” effect. The underlying molecular mechanisms that lead to the differences in biophysical and biological properties observed between enantiopure and racemic Aβ42 remain subject of active research in our laboratory.

BIO

TBD

Information for BPS Presenters

The Boulder Peptide Foundation was established to further the science and knowledge of peptide technology to develop novel therapeutics, biomaterials, medical diagnostics and other beneficial uses for mankind. As part of this goal we run several programs to support career advancement, seminars and educational events. Join us on our mission to expand the applications of peptide science.

Information for BPS Presenters

The purpose of the Boulder Peptide Symposium is to encourage sharing of information related to peptide therapeutic development with an emphasis on the technical, scientific and regulatory aspects of the pharmaceutical development. Presentations that demonstrate original thinking or share experiences from case studies in product development shall receive priority over others.

The Boulder Peptide Symposium offers multiple opportunities for participants to present.

Oral Presentations in Scientific Sessions

The session topics for Scientific Program are Peptides in the Clinic, Drug Delivery, Chemistry of Complex Peptides, Spotlight on Discovery, and Peptide Showcase. Abstracts may be submitted via the Apply to Present page on the website. Submissions will be reviewed by the Scientific Advisory Board on a monthly basis and the speaker will be notified of a decision.

Presentation length: Format is 25-30 minutes slide presentation with 5-10 minutes for Q&A, with the exception of Peptide Showcase talks which are 10 minute slide presentations with 5 minutes for Q&A. Please confirm with your session chair to confirm the exact presentation length.

Invited Speakers: Speakers are requested to supply their presentation details 30 days after receiving an invitation to present.

Program Book Deadline: Final abstract and title must be provided no later than September 1st. No changes to the program are possible after this date.

Presentation Format: Oral presenters please provide your presentation slides to the A/V table on the day of your presentation.

Lodging: All speakers are requested to reserve their own room. Discount rates at the conference hotel are available until August 16th.

Registration: All speakers, excluding sponsored presentation speakers, receive a complimentary registration upon approval of the abstract.

Peptide Showcase Description

The Peptide Showcase is an opportunity for an individual or company to “showcase” new ideas, technology and pipeline assets. Priority shall be given to presentations from biotech and startup companies. Service providers and vendors are not eligible. Speakers in the session receive a complimentary event registration.

Posters

Posters can be presented on any topic relevant to peptides including original research, innovative products and technologies.

Eligibility- Any attendee (from academia, industry, biotech or vendor/sponsor) can present a poster. The presentation must contain original scientific thinking. To submit a poster go to the Submit a Poster link from the meeting menu. All submissions are reviewed on a rolling basis and will be notified of approval. September 1st is the last day to submit a poster abstract. Approved posters are published on the BPF website.

A 30 ” x 40″ board shall be provided with thumb tacks. Board will be on an easel and can be rotated for either landscape or portrait formats. Once you apply for a poster, you will get email confirmation that your poster was accepted. The poster session and number assignments will be emailed one week before the Symposium.

Poster boards shall be available for display from 8am to 8pm the day of your assigned poster session. See the program agenda for the poster session schedule.

Public Release

Every presentation at the Boulder Peptide Symposium is automatically recorded. Speakers are required to give consent for sharing of the presentation video with the peptide community.